Clinical Trials on Pulmonary Disease (COPD), Chronic Obstructive in Poland

Total 3131 results

Medical University of Lodz
National Science Centre, Poland

Completed

Improvement in COPD Elderly Patients Health: Study Protocol

Chronic Obstructive Pulmonary Disease (COPD)

Poland
Medical University of Lodz

Completed

A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management (TICD-COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
Medical University of Lodz

Completed

HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Poland
Medical University of Warsaw

Unknown

Effects of Osteopathic Techniques on Residual Volume in Severe Chronic Obstructive Pulmonary Disease

COPD

Poland
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
AstraZeneca

Completed

The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Memorial Hospital of Rhode Island
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Translating The GOLD COPD Guidelines Into Primary Care Practice (LungAge)

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Terminated

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease | COPD

Poland, Sweden
AstraZeneca

Completed

Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus)

Moderate to Severe COPD

Sweden, Bulgaria, Poland, Denmark, Slovakia
AstraZeneca

Completed

Aclidinium/Formoterol Fixed Combination Dose Finding Study

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Australia, Czech Republic, Poland
Novartis

Completed

A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Spain, Germany, South Africa, Australia, Poland, New Zealand, Netherlands
AstraZeneca

Completed

The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

Chronic Obstructive Pulmonary Disease, COPD

France, Poland, South Africa, Spain, United States, Canada, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. (TRIPLE10)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
AstraZeneca
Parexel

Completed

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Chronic Obstructive Pulmonary Disease - COPD

United States
Dey

Completed

A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Medical University of Bialystok
Medical Research Agency, Poland

Recruiting

Atorvastatin Effect on Reduction of COPD Exacerbations (Captain)

Smoking | Copd | COPD Exacerbation | Gene Expression | Atorvastatin

Poland
AstraZeneca

Completed

Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | COPD

Poland, United Kingdom, Germany, Sweden, Denmark
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)

Chronic Obstructive Pulmonary Disease | COPD

Austria, France, Hungary, Italy, Poland, Portugal, Russian Federation, South Africa, Spain, Canada, United Kingdom, Australia, Netherlands, Switzerland
Medical University of Bialystok

Completed

The Effects of Atorvastatin Treatment in COPD Patients

COPD

Poland
Novartis Pharmaceuticals

Completed

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Chronic Obstructive Pulmonary Disease, COPD

Poland, United States
AstraZeneca

Completed

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Chronic Obstructive Pulmonary Disease | COPD

United States, France, Poland, South Africa, Canada, Germany
Novartis

Completed

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Spain, Turkey, France, Netherlands, Germany
Weill Medical College of Cornell University
National Heart, Lung, and Blood Institute (NHLBI); University of Michigan; Duke... and other collaborators

Completed

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 2) (CAPTURE)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Franciscus Gasthuis

Recruiting

Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease (TRICOLON)

Copd | Adherence, Medication

Netherlands
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
Kaiser Permanente
Merck Sharp & Dohme LLC

Completed

A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease

Asthma | COPD

United States
Edmond Pharma

Unknown

The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD) (RESTORE)

Chronic Obstructive Pulmonary Disease (COPD)

Belgium, Bulgaria, Czech Republic, Denmark, France, Italy, Poland, Romania, Slovakia, United Kingdom
Sunovion Respiratory Development Inc.

Completed

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-5)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Czechia, Hungary, Russian Federation
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Czech Republic, Germany, Hungary, Poland
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, United States, Canada, India, Italy, Poland, South Africa
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Erasmus Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

PCT-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations (PRECISION)

COPD | COPD Exacerbation | Acute Copd Exacerbation

Netherlands
Weill Medical College of Cornell University
National Heart, Lung, and Blood Institute (NHLBI); University of Michigan; Duke... and other collaborators

Completed

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 1) (CAPTURE)

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
Weill Medical College of Cornell University
National Heart, Lung, and Blood Institute (NHLBI); University of Michigan; Duke... and other collaborators

Completed

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3) (CAPTURE)

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Czech Republic, Poland, Hungary, Romania, Slovakia
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, United Kingdom, United States, Australia, Austria, Brazil, Hungary, New Zealand, Romania, Russian Federation
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST1)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Argentina, Germany, Spain, Turkey, Guatemala, Mexico, Australia, Denmark, South Africa, Philippines
Chiesi Farmaceutici S.p.A.

Completed

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (GLIMMER)

Chronic Obstructive Pulmonary Disease | COPD

United States
AstraZeneca

Completed

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Oregon Health and Science University
4DMedical

Enrolling by invitation

Ventilation Imbalances in Mild to Moderate Chronic Obstructive Pulmonary Disease (VAPOR)

Lung Diseases | COPD | Respiratory Disease | Dyspnea

United States
VA Office of Research and Development

Completed

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease (TADA-PHILD)

Pulmonary Hypertension | Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Korea, Republic of, Argentina, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Canada, India, Bulgaria, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST2)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Spain, Canada, Slovakia, India, Netherlands, Czech Republic, Hungary
AstraZeneca

Completed

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom

Clinical Trials on Pulmonary Disease (COPD), Chronic Obstructive in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations